The $349 Wegovy Price Cut: A Full Pricing Timeline

The $349 Wegovy price cut was the largest branded GLP-1 pricing change in history. Here's the full timeline from pre-cut baseline to current subscription tiers.

On November 17, 2025, Novo Nordisk announced the most significant pricing change in Wegovy's commercial history: a cash-pay program offering the drug at $349 per month through the NovoCare direct-to-consumer channel, with a $199 introductory price for qualifying new patients. The announcement was the single largest branded GLP-1 price cut in dollar terms and reshaped the commercial pricing landscape within weeks.

This pricing timeline walks through the actual sequence of events: what came before the cut, what the announcement contained, what followed, and what the current NovoCare program looks like as of April 2026.

Pre-Cut Baseline: 2024 Wegovy Pricing

Prior to the November 2025 cut, Wegovy's list price was approximately $1,349 per month, with actual cash-pay pricing varying by pharmacy and manufacturer savings card availability. Commercially-insured patients with coverage paid copays typically ranging from $25 to $250, depending on plan design. Uninsured cash-pay patients typically paid $1,000-$1,300 at retail pharmacies. Wegovy was broadly perceived as expensive, and access was constrained more by cost than availability.

Timeline of the Pricing Shift

What NovoCare Actually Is

NovoCare is Novo Nordisk's direct-to-consumer commercial channel for cash-pay patients. The program bypasses traditional pharmacy benefit manager intermediation and offers Wegovy at the manufacturer's cash-pay price through authorized pharmacy partners and telehealth distribution partners. The $349 monthly price is the standard program price; the $199 introductory price applies to qualifying first-month orders under specific promotional terms.

The program is designed for uninsured patients, insured patients whose plans don't cover weight-management medications, and patients who find their commercial copay exceeds the NovoCare cash-pay price. It is not designed as a substitute for Medicare or Medicaid coverage.

The Market Reaction

The $349 announcement generated immediate responses from competitors, telehealth partners, and investor analysts. Lilly followed within two weeks with Zepbound vial pricing at $299/$399/$449 depending on dose strength. Telehealth brands that had been reliant on compounded semaglutide began negotiations with Novo for authorized Wegovy distribution at preferred pricing. The Hims partnership announced March 9, 2026 was the largest of these.

The subscription tier at $249/month, launched March 31, 2026 through Hims, Ro, WeightWatchers, LifeMD, and Sesame Care, is slightly below the NovoCare direct price and represents the lowest currently available cash-pay price for brand-name injectable semaglutide in the U.S. market.

What the Cut Actually Enabled

The business logic behind Novo's price cut was straightforward: the pre-cut price of $1,349 generated high per-unit revenue but limited total volume. Substantial portions of the market — uninsured patients, patients whose plans didn't cover GLP-1s, patients priced out at retail — were inaccessible at that price point. A $349 price accesses that broader market at lower per-unit revenue but meaningfully higher total volume. The math depends on the demand elasticity, and Novo's analysis evidently concluded that the broader market was large enough to justify the price change.

Novo's 2025 annual report and Q4 2025 investor call explicitly framed the NovoCare pricing as a response to "competitive dynamics and patient affordability considerations." Translated: compounded alternatives had captured a meaningful share of cash-pay patients, Medicare negotiation was coming, and competitors were already cutting prices.

Current Pricing Landscape

As of April 2026, Wegovy pricing is tiered across channels: $249/month via authorized telehealth subscription, $349/month via NovoCare direct, ~$499/month at major retail pharmacy cash-pay, and $149/month for the lower-dose oral Wegovy starting point. The commercial insurance experience varies by plan. Medicare Part D pricing will shift materially when the negotiated Maximum Fair Price takes effect January 1, 2027.

For related reporting, see our Zepbound vial pricing breakdown and Medicare 71% discount analysis.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.